XML 65 R36.htm IDEA: XBRL DOCUMENT v3.8.0.1
Business Agreements (Details)
12 Months Ended
Oct. 25, 2017
USD ($)
treatment
Dec. 18, 2013
USD ($)
Dec. 31, 2017
USD ($)
treatment
shares
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Variable Interest Entity          
Revenues     $ 295,000 $ 653,000 $ 277,000
Amount contributed   $ 1,500,000      
Equity interest   50.00%      
Percentage of ownership control with disputes resolved through arbitration   50.00%      
Voting rights     50.00%    
Loss from equity method investment     $ (1,018,000) (1,542,000) (1,561,000)
Investment in joint venture     146,000 65,000  
Additional contribution in joint venture     1,100,000 1,750,000 1,500,000
OvaXon, LLC          
Variable Interest Entity          
Loss from equity method investment     (1,000,000) (1,500,000) $ (1,500,000)
Investment in joint venture     $ 100,000 100,000  
OvaTure Collaboration          
Variable Interest Entity          
Period of commercial milestone payment after the first commercial sale of collaborative arrangement     3 months    
MGH and Harvard          
Variable Interest Entity          
License and patent-related fees     $ 400,000    
Contingent milestone payments     10,700,000    
IVF Japan          
Variable Interest Entity          
Initial term of agreement (in years) 1 year        
Period of material breach (in years) 30 days        
Fixed fee revenue per treatment cycle $ 1,000        
Reimbursed amount of lab operations and personnel costs $ 200,000   55,000    
Number of excess treatment cycles | treatment 100        
Fixed fee revenue per excess treatment cycle $ 2,000        
Revenues     63,400    
Fees for treatment cycles $ 50,000   $ 8,400    
IVF Japan | Minimum          
Variable Interest Entity          
Number of excess treatment cycles | treatment     50    
Intrexon          
Variable Interest Entity          
Amount contributed   $ 1,500,000      
Equity interest   50.00%      
Percentage of ownership control with disputes resolved through arbitration   50.00%      
Additional contribution in joint venture     $ 1,100,000 $ 1,800,000  
Intrexon | OvaTure Collaboration          
Variable Interest Entity          
Issuance of common stock shares upon execution of collaborative arrangements (in shares) | shares     273,224    
Vesting of Founders Stock     $ 2,500,000    
Technology access fee payable in cash upon specified passage of time     $ 2,500,000